Antimicrobial Resistance Diagnostics Market: as national AMR action plans mandate documented rapid testing before antibiotic prescribing, clinical microbiological capacity is moving from reference laboratory settings to frontline hospital wards, so demand concentrates on automation platforms generating multi-year reagent annuities, and the value gap between installed-base incumbents and early-stage point-of-care entrants is widening rather than closing.

The global antimicrobial resistance diagnostics market size was USD 3.36 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as mandatory national antimicrobial stewardship programme requirements, verified high single-digit growth in hospital microbiology platform volumes, and accelerating point-of-care AST technology development. The first driving factor is the WHO Global Action Plan on Antimicrobial Resistance, implemented through National Action Plans across 138 countries, which establishes surveillance and stewardship requirements that mandate institutional AMR diagnostic capability at participating healthcare systems, with more than 5,700 US Joint Commission-accredited acute care hospitals now required to document antimicrobial stewardship programme activities including rapid diagnostic testing before antibiotic prescribing decisions. The second driving factor is confirmed reagent-volume growth on installed automation platforms, with verified primary company financial disclosures establishing that hospital AMR diagnostic test volume is growing at 7 to 9% annually, driven by expanding MALDI-TOF and automated phenotypic AST installed bases at acute care hospitals in North America and Europe as well as growing molecular panel adoption. The third driving factor is the maturation of point-of-care AST technology addressing the community prescribing market, where miniaturised nanofluidic and microchip-based platforms are creating a new addressable commercial segment beyond the existing hospital microbiology laboratory installed base. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way automated phenotypic AST platforms generate multi-year consumable annuities once placed in a hospital microbiology laboratory, which allows incumbent platform revenue to compound without requiring a new capital sale at each account. Once a VITEK 2 or BD Phoenix system is installed, each incremental test run adds reagent revenue without rebuilding the customer relationship or re-winning a capital procurement cycle, so the reagent annuity compounds in value as the installed base grows around it. As a result, demand and revenue share are concentrating around large installed-base platforms that hold deep formulary integration and long replacement cycles, and the forecast tilts toward these incumbents rather than single-test entrants that require a fresh capital commitment at each new account. For instance, in March 2025, bioMerieux received FDA approval for its VITEK COMPACT PRO system targeting the mid-tier hospital segment, and the company identified approximately 2,000 to 3,000 US community hospitals currently running manual disk diffusion as the addressable market for the new system, one of more than two dozen platform extensions bioMerieux has executed against its single VITEK reagent architecture. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the WHO Global Action Plan on Antimicrobial Resistance, adopted by the World Health Assembly in 2015 and implemented through National Action Plans across 138 countries by 2024, which establishes surveillance, prevention, and stewardship requirements mandating institutional AMR diagnostic capability at participating healthcare systems. AMR stewardship works only if diagnostic results are available fast enough to guide the prescribing decision, and the Joint Commission standard for antimicrobial stewardship programmes at US acute care hospitals increasingly requires documented rapid diagnostic testing before antibiotic de-escalation decisions, so AMR diagnostic testing and stewardship programme compliance arrive together as a package requirement. The recent record shows the pace. More than 5,700 US Joint Commission-accredited acute care hospitals are now subject to this requirement, and the CDC's 2023 Antibiotic Resistance Threats report identified 18 AMR threat organisms and documented more than 2.8 million antibiotic-resistant infections annually in the United States alone, with over 35,000 attributable deaths, sustaining CMS reimbursement for phenotypic susceptibility testing. In January 2026, the WHO published updated implementation guidance for national AMR surveillance systems naming rapid molecular diagnostics and automated phenotypic AST as the two required diagnostic modalities for hospital-level AMR stewardship data submission, and Selux Diagnostics received FDA clearance in February 2025 for its next-generation rapid blood culture AST system reducing time to actionable results below six hours. The effect on the market is that policy mandate creates a floor demand that is structurally resistant to cyclical procurement slowdowns, because hospitals must maintain AST capability to retain accreditation, making AMR diagnostic test volume a recurring institutional cost rather than a discretionary capital purchase. These are some of the key factors driving revenue growth of the market.

The second driver is the reagent annuity model of installed automation platforms, where each incremental test adds consumable revenue without rebuilding the customer relationship or re-winning a capital procurement cycle. Automated phenotypic AST platforms including VITEK 2, BD Phoenix, and BD Kiestra generate 5 to 10 years of reagent revenue per placement, and molecular IVD panels on GeneXpert and BD MAX generate per-cartridge consumable revenue from each patient sample processed, so the commercial return is a function of test volume on installed capacity rather than new instrument sales. bioMerieux reported microbiology sales growth of 8.3% for full-year 2024 per its March 2025 earnings press release, driven by reagent volume and price increases across VITEK automated AST, blood culture, and BIOFIRE systems, with the SPOTFIRE solution reaching approximately 3,000 instruments installed by year-end 2024. BD reported high single-digit growth in its Microbiology platforms across consecutive fiscal 2024 quarterly earnings disclosures, and BD MAX and BD COR molecular IVD systems both achieved double-digit growth in fiscal 2024 per BD's November 2024 full-year earnings press release. The effect on the market is that reagent-anchored revenue produces high revenue visibility and low churn rates, and the VITEK COMPACT PRO FDA approval in March 2025 extends this annuity model to the mid-tier hospital segment previously reliant on manual disk diffusion, expanding the addressable reagent base by an estimated 2,000 to 3,000 US community hospitals. These are some of the key factors driving revenue growth of the market.

bioMerieux's 8.3% microbiology revenue growth in FY2024 and BD's confirmed high single-digit microbiology platform growth across four consecutive quarterly earnings disclosures establish that hospital AMR diagnostic test volume growth at 7 to 9% annually is structural and reagent-consumption driven. The VITEK COMPACT PRO FDA approval in March 2025 extends this annuity model to an estimated 2,000 to 3,000 additional US community hospitals previously running manual disk diffusion.

The third driver is the commercial maturation of point-of-care AST technology platforms that bring susceptibility testing outside the hospital microbiology laboratory and into community prescribing settings. POC AST works only if the device can return an actionable result within the duration of a clinical consultation, and nanofluidic microchannels and electrochemical microchip detection now enable clinically valid AST results in 30 to 90 minutes from a urine or blood sample without requiring laboratory equipment or trained microbiologists. In June 2024, Sysmex Astrego was awarded the Longitude Prize on AMR for its PA-100 AST System using nanofluidic technology to detect UTI antibiotic susceptibility within 30 minutes at the point of care, and iFAST Diagnostics announced USD 6.5 million in seed funding in November 2024 to commercialise its microchip-based technology determining antibiotic effectiveness within three hours, expanding the pipeline of POC AST platforms targeting the community prescribing gap. The effect on the market is that POC AST creates a revenue-generating category above the existing hospital laboratory market, because the approximately 8 million annual UTI antibiotic prescriptions written by NHS GPs in England alone represent an addressable diagnostic market that did not previously exist for AMR diagnostics companies, and Longitude Prize validation accelerates technology assessment and early adoption commissioning by European national health systems. These are some of the key factors driving revenue growth of the market.

However, the AMR diagnostics market faces adoption constraints from the high capital and operational cost of advanced molecular and NGS-based platforms in low- and middle-income countries. Because PCR and NGS-based AMR platforms require USD 50,000 to USD 200,000 capital investments and trained microbiological laboratory personnel, the majority of global AMR burden concentrated in LMIC settings cannot access advanced resistance testing beyond urban academic hospital reference laboratories, so adoption remains limited to tertiary care even where disease prevalence is highest. Healthcare pricing reform compounds this, because volume-based procurement programmes and reductions in immunoassay reimbursement rates in major regulated markets, including China where Roche Diagnostics documented the impact on its diagnostics business in its January 2025 full-year earnings, compress revenue growth below underlying volume growth, and the same pricing dynamics identified by BD in its consecutive FY2024 quarterly disclosures illustrate that even large installed-base markets face margin pressure that narrows the commercial return on new platform investment. Entrenched empirical antibiotic prescribing is the third constraint, since clinical cultures of prescribing without rapid diagnostics are deeply embedded in community and lower-acuity settings across both high-income and lower-income markets, so the cost of driving behaviour change at scale is not always recovered, and point-of-care AST platforms without an established reimbursement pathway struggle to achieve broad commercial adoption beyond specialist referral centres. These factors substantially limit antimicrobial resistance diagnostics market growth over the forecast period.

Based on technology, the global AMR diagnostics market is segmented into Microbiology Culture & Phenotypic AST, PCR & Molecular Diagnostics, MALDI-TOF Mass Spectrometry, NGS-Based Resistance Genotyping & Surveillance, and Rapid & Point-of-Care AST. Microbiology Culture & Phenotypic AST holds the largest revenue share, because the large installed base of automated VITEK and BD Phoenix systems at hospital microbiology laboratories globally generates multi-year reagent annuity revenue that is structurally resistant to competitive displacement, which suits the hospital procurement model of long replacement cycles and formulary commitment. MALDI-TOF and conventional culture media remain established for routine pathogen identification and single-organism susceptibility panels, and they are more cost-effective per test than molecular panels for straightforward bacteraemia cases, but they cannot deliver the multiplexed resistance gene profiling required for outbreak surveillance and NGS-linked stewardship reporting. Liquid biopsy-equivalent metagenomics sequencing for culture-independent AMR gene detection is expected to register the fastest revenue growth rate in the global AMR diagnostics market over the forecast period, driven by falling sequencing costs and adoption by reference laboratory networks, which is why Illumina and Oxford Nanopore Technologies are both expanding their clinical metagenomics reagent portfolios targeting hospital infection control leads. These are some of the key factors driving revenue growth of the market.

Based on pathogen, the global AMR diagnostics market is segmented into MRSA & Drug-Resistant Staphylococci, Clostridioides difficile, CRE & ESBL-Producing Gram-Negatives, Drug-Resistant Streptococcus pneumoniae, and Drug-Resistant Gonorrhoea & Other Pathogens. MRSA & Drug-Resistant Staphylococci holds the largest revenue share, because MRSA screening and surveillance is mandated at admission by national infection control guidelines across North America and Europe, generating high-volume routine molecular testing that sustains the GeneXpert MRSA and similar rapid PCR platform installed bases at acute care hospitals globally, which suits the high-throughput automated molecular testing model of large clinical microbiology laboratories. Clostridioides difficile PCR testing is expected to register a rapid revenue growth rate in the global AMR diagnostics market over the forecast period, driven by expanding mandatory C. diff surveillance requirements and the regulatory validation of multiplex GI panels, which is why Danaher/Cepheid continues to expand its GeneXpert C. diff panel installed base across European hospital networks. These are some of the key factors driving revenue growth of the market.

Based on application, the global AMR diagnostics market is segmented into Hospital-Acquired Infection Diagnostics, Antimicrobial Stewardship Programme Support, and Epidemiological Surveillance & Outbreak Control. Hospital-Acquired Infection Diagnostics holds the largest revenue share, because HAI prevention is subject to regulatory reporting requirements and reimbursement penalties at accredited hospitals globally, creating a recurring institutional testing mandate for blood culture, MRSA screening, and C. diff surveillance that generates consistent high-volume diagnostic test orders independent of prescribing culture change initiatives, which aligns with the consumable-volume growth model of installed automated platforms. Antimicrobial Stewardship Programme Support is expected to register a rapid revenue growth rate in the global AMR diagnostics market over the forecast period, driven by the expansion of mandatory stewardship programme requirements under national AMR action plans and US Joint Commission standards, which is why bioMerieux and BD are both investing in digital antibiogram analytics tools that integrate AST result data with real-time stewardship guidance for clinical pharmacists. These are some of the key factors driving revenue growth of the market.

Based on regional analysis, the AMR diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the CDC and Joint Commission antimicrobial stewardship programme mandate requires documented rapid diagnostic testing at all accredited acute care hospitals, and because the major installed-base AMR diagnostics companies including bioMerieux, Becton Dickinson, Danaher/Cepheid, and Thermo Fisher Scientific are all headquartered or hold their primary US commercial operations in North America. bioMerieux's VITEK 2 system holds an installed base at more than 1,700 North American hospital microbiology laboratories per the company's confirmed commercial disclosures, representing a reagent annuity base that sustains consistent double-digit microbiology consumable revenue in the region. The concentration of major academic medical centres and reference microbiology laboratories in the United States also means that new AMR diagnostic platforms including POC AST and clinical metagenomics panels are typically launched in the United States first before European or Asia Pacific regulatory submissions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and the Netherlands represent the four largest European national AMR diagnostics markets, with Roche Diagnostics holding a strong immunodiagnostic and cobas molecular platform installed base across German and Swiss hospital systems, and bioMerieux maintaining deep penetration in French and Southern European clinical microbiology laboratories. The European CE-IVDR regulatory framework governing in vitro diagnostic devices applies stringent performance evidence requirements that increase the cost and timeline for European market entry, and national reimbursement systems across Europe vary significantly in the speed with which they adopt new AMR diagnostic technologies following regulatory approval. The result is steady rather than rapid growth, shaped more by regulatory compliance and installed-base expansion than by new technology adoption cycles.

The market in Asia Pacific is expected to register a fastest revenue growth rate over the forecast period. China, Japan, South Korea, and India represent the four largest Asia Pacific national AMR diagnostics markets, with India's Ministry of Health announcing in January 2024 its plan to extend AMR surveillance to nationwide secondary care hospitals, and bioMerieux confirming 11% APAC growth in its Q4 2024 results driven by microbiology and BIOFIRE platform demand in China, South Korea, and Southeast Asia. China's volume-based procurement programme moderated immunodiagnostic reimbursement rates and created headwinds for Roche's diagnostics revenue in the country per Roche's January 2025 full-year earnings, but overall APAC molecular AMR diagnostics volume growth remained positive. The breadth of APAC hospital expansion programmes and the relatively lower installed-base penetration of automated phenotypic AST at community hospitals leaves more room for growth than in North America or Europe.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national AMR diagnostics markets in the region, with bioMerieux confirming that Latin America delivered 14% growth in Q4 2024 across BIOFIRE, microbiology, and VIDAS product lines with both equipment and reagent demand reaching double-digit growth. AMR diagnostic access concentrates in urban tertiary hospital settings in Sao Paulo, Mexico City, and Buenos Aires, with public hospital procurement constrained by government budget cycles and foreign exchange volatility. Indirect effects of Iran-US sanctions on South American freight routes have maintained elevated import costs for temperature-sensitive reagents and instrument components at Brazilian hospital clinical microbiology laboratories, compounding the cost-of-access barrier for advanced molecular and NGS platforms and slowing adoption of PCR and MALDI-TOF systems beyond the major urban reference laboratory networks through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, the United Arab Emirates, and South Africa represent the primary commercial AMR diagnostics markets in the region, with Gulf Cooperation Council government hospital investment programmes sustaining demand for automated phenotypic AST and molecular AMR panels at major public hospital systems in Riyadh and Abu Dhabi. South Africa is the most established market on the continent, with the National Health Laboratory Service operating a national AMR reference laboratory network that generates consistent phenotypic AST and molecular surveillance testing volume, while the Gulf states are still building the clinical microbiology laboratory capacity and trained personnel base needed for broad automated AMR diagnostic deployment from a relatively early starting point.